A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of HSK21542 Injection in Subjects Undergoing Hemodialysis
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blind, placebo-controlled phase II clinical trial.
The main objective is to evaluate the safety, pharmacokinetics, and efficacy of HSK21542
injection in subjects undergoing hemodialysis
Phase:
Phase 2
Details
Lead Sponsor:
Haisco Pharmaceutical Group Co., Ltd. Sichuan Haisco Pharmaceutical Group Co., Ltd.